Olaparib (OL), a PARP inhibitor with a molecular weight of 435.08 g/mol and a formula structure of C24H23FN4O3 (Figure 1B), has revolutionized cancer therapy, particularly for BRCA1/2-mutated cancers. This evidence concerns the gene BRCA1 and cancer.